RenovoRx, Inc. (NASDAQ:RNXT – Get Rating) was the target of a large decline in short interest in the month of May. As of May 15th, there was short interest totalling 13,000 shares, a decline of 49.6% from the April 30th total of 25,800 shares. Based on an average trading volume of 52,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.2% of the shares of the company are sold short.
RenovoRx Stock Performance
NASDAQ RNXT traded down $0.02 on Friday, hitting $1.88. 509 shares of the company’s stock traded hands, compared to its average volume of 51,533. RenovoRx has a 1-year low of $1.50 and a 1-year high of $5.75. The firm’s 50-day moving average price is $2.77 and its two-hundred day moving average price is $2.85.
RenovoRx (NASDAQ:RNXT – Get Rating) last posted its earnings results on Thursday, March 2nd. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.03. As a group, analysts predict that RenovoRx will post -1 earnings per share for the current year.
Hedge Funds Weigh In On RenovoRx
RenovoRx Company Profile
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
- Get a free copy of the StockNews.com research report on RenovoRx (RNXT)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.